TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01414075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Tiered, weight-based dosing per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Tiered, weight-based dosing per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Tiered, weight-based dosing per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Tiered, weight-based dosing per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Iron
Description: Administered per oral dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Iron
Description: Administered per oral dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron
Description: Administered per IV dose and schedule specified in the arm.
Study: NCT03460483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Undergo genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo tumor screening via next-generation sequencing
Study: NCT02408458

Intervention type: DEVICE
Group type: OTHER
Intervention: MIROMESH®
Study: NCT00969202

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery using the Novalis Tx
Description: Five treatments given every other day.
Study: NCT02103556

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil
Description: 4 ml daily (adjusted as needed), for 4 weeks
Study: NCT02813954

Intervention type: DEVICE
Intervention: Blood Gas Sampling
Description: analyzing amniotic fluid by blood gas device
Study: NCT02955199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothering From the Inside Out (MIO)
Description: Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
Study: NCT02568085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista
Description: Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista
Description: Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
Study: NCT02867787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox arm
Study: NCT02967497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YQ1
Description: Oral administered powder
Study: NCT03541824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Acceptance Program
Description: The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
Study: NCT02793102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory workshop
Description: Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somesthesia workshop
Description: Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somesthesia workshop
Description: Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory workshop
Description: Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
Study: NCT02533154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prosicca
Description: Prosicca eyedrops Dosage: on demand Route of administration: topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prosicca sine
Description: Prosicca sine eyedrops Dosage: on demand Route of administration: topical

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: bacterial cultures obtained with conjunctival swabs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bacterial culture
Description: bacterial cultures obtained with conjunctival swabs
Study: NCT02738450

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACI-24 low dose
Description: ACI-24 administered as a sterile suspension in PBS via s.c. injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACI-24 high dose
Description: ACI-24 administered as a sterile suspension in PBS via s.c. injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a standard PBS sterile solution administrated via s.c. injection.
Study: NCT02955199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
Study: NCT00605306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol maleate/mometasone furoate
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
Study: NCT00326196

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: percutaneous coronary stenting with drug eluding stents

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Description: coronary bypass
Study: NCT00504855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casting using Gortex (waterproof) cast padding materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casting using cotton/cotton-poly cast padding materials
Study: NCT02235675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack-It Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
Study: NCT03477851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: Tramadol i.m. simultaneous with sciatic nerve block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9%NaCl i.m. simultaneous with sciatic nerve block
Study: NCT02031835

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BWSTT (3 days a week for maximum of 20 minutes session)
Study: NCT03130387

Intervention type: DEVICE
Group type: OTHER
Intervention: Office Hysteroscope
Description: Diagnosis of C.S niche in patients wit AUB by office hysteroscope
Study: NCT00223977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex
Description: 125 mg weekly x 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex
Description: 250 mg weekly x 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: 325 mg ferrous sulfate orally three times daily x 8 weeks
Study: NCT03828422

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Study: NCT01818258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZDV+3TC+LPV/r

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZDV+3TC+LPV/r
Study: NCT01025349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, docetaxel, cisplatin
Description: Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
Study: NCT03350087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS+cTBS group
Description: In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham theta burst stimulation
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT
Description: The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT+optimal rTMS group
Description: In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
Study: NCT03122353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene and betamethasone suspension
Description: Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex
Description: Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle used as placebo
Study: NCT03649529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPA-TriMAR-T
Description: Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
Study: NCT02583230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedLink System
Description: Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
Study: NCT03661905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
Study: NCT01985490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epiretinal membrane and internal limiting membrane removal
Description: fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
Study: NCT02342613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated PTCy-MILs
Description: The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
Study: NCT03260894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat 100 mg administered orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Pazopanib 800 mg administered orally once daily.
Study: NCT03970096

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study: NCT00326196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Description: coronary bypass
Study: NCT01462175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Study: NCT00481572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: titrated norepinephrine over a period of 48 hrs
Study: NCT00678925

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine
Description: 850 mg per day from 18 weeks pregnancy through 90 days postpartum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil placebo
Description: Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
Study: NCT02139241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: 0.3 mg IV as bolus before induction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline as bolus before induction of general anesthesia
Study: NCT03754660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1237592
Description: Oral inhalation with dry powder inhaler, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1237592
Description: Oral inhalation with dry powder inhaler, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1237592
Description: Oral inhalation with dry powder inhaler, single dose.
Study: NCT03069391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise alone (PES) first
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive exercise alone (iCE) first
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interactive Physical and Cognitive Exercise (iPACES™)
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interactive Physical and Cognitive Exercise (iPACES™)
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
Study: NCT03106259

Intervention type: DRUG
Intervention: FURESTEM-RA Inj.
Description: Non-interventional observational study
Study: NCT03437525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
Study: NCT02331836

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arc Endocuff (AEC 110, 120, 130, 140)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap
Description: Olympus Disposable distal attachment 15mm diameter, 4mm depth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscope
Study: NCT01949350

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate protein
Description: Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starved
Description: Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
Study: NCT02242409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Abraxane
Description: Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
Study: NCT02970409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline
Description: catheter lock using saline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: catheter lock using Heparin